Fore Pharmas latest report ‘Global Ocular Hypertension Drug Pipeline Capsule – 2011 is an outline of all the key research and development (R&D) activities of the global ocular hypertension drug market. It covers information on key pipeline molecules in various stages of R&D including all the phases of clinical trials, preclinical research, and drug discovery. The report is up-to-date with full coverage of the licensing activities and partnerships.

This report helps executives to keep a track of their competitors and understand their pipeline molecules. The information presented in this report can be used for identifying the partners, prioritizing, evaluating opportunities, developing business development strategies, and executing in-licensing and out-licensing deals.

The report provides information on pipeline molecules by company and mechanism of action across the different stages of R&D. It includes registered / preregistered stage, phase 3 clinical trial, phase 2 clinical trial, phase 1 clinical trial, preclinical research, and drug discovery. It also provides information on pipeline molecules developed in leading geographies including the U.S., Canada, France, Germany, U.K., Italy, and Spain by various stages of R&D. Licensing activities and partnerships in the ocular hypertension drug market is thoroughly covered by company and licensee with the deal summary.

Key Features of the Report:
- Ocular Hypertension: Overview
- Ocular Hypertension Drug Pipeline Overview
- Ocular Hypertension Phase 3 Clinical Trial Drug Pipeline Insights
- Ocular Hypertension Phase 2 Clinical Trial Drug Pipeline Insights
- Ocular Hypertension Phase 1 Clinical Trial Drug Pipeline Insights
- Ocular Hypertension Preclinical Research Drug Pipeline Insights
- Ocular Hypertension Drug Discovery Pipeline Insights
- Geographic Landscape of Ocular Hypertension R&D Activities
- Ocular Hypertension R&D Activities in North America
- Ocular Hypertension R&D Activities in Europe
- Licensing Activities / Partnerships in the Global Ocular Hypertension Drug Market

1. Ocular Hypertension: Disease Definition
2. Ocular Hypertension Drug Pipeline Overview
3. Ocular Hypertension Phase 3 Clinical Trial Drug Pipeline Insights
4. Ocular Hypertension Phase 2 Clinical Trial Drug Pipeline Insights
5. Ocular Hypertension Phase 1 Clinical Trial Drug Pipeline Insights
6. Ocular Hypertension Preclinical Research Drug Pipeline Insights
7. Ocular Hypertension Drug Discovery Pipeline Insights
8. Geographic Landscape of Ocular Hypertension R&D Activities
8.1 Ocular Hypertension R&D Activities in North America
8.2 Ocular Hypertension R&D Activities in Europe
9 Licensing Activities / Partnerships in the Global Ocular Hypertension Drug Market
10 Research Methodology Table 1: Ocular Hypertension Drug Pipeline: Phase 3 Clinical Trial

Table 2: Ocular Hypertension Drug Pipeline: Phase 2 Clinical Trial
Table 3: Ocular Hypertension Drug Pipeline: Phase 1 Molecules
Table 4: Ocular Hypertension Drug Pipeline: Preclinical Research
Table 5: Ocular Hypertension R&D Activities by Geography
Table 6: Ocular Hypertension Drug Pipeline: North America
Table 7: Ocular Hypertension Drug Pipeline: Europe
Table 8: Ocular Hypertension Drug Pipeline: Licensing Activities

Figure 1 : Ocular Hypertension Drug Pipeline Molecules by Stages
Figure 2 : Ocular Hypertension R&D Activities by Geography